Ategenos Secures Foundational U.S. Patent for First SmartPatch Platform Targeting $1T+ Medication Non-Adherence Crisis

Only platform enabling real-time detection and intervention for medication non-adherence at community scale

CAMBRIDGE, Mass., Aug. 5, 2025 /PRNewswire/ — Ategenos, a pharmatech company tackling the $1T global cost of medication non-adherence, today announced it has been awarded a foundational U.S. patent protecting the core architecture of its wearable SmartPatch™ platform. The patent positions Ategenos as a category-defining innovator at the convergence of drug delivery, digital health, and real-world evidence.

U.S. Patent No. 12,329,861, covers Ategenos’s proprietary integration of transdermal drug delivery with low-cost, disposable electronics that wirelessly notify caregivers—wherever they are—when an at-risk patient misses a dose of their critical medicine.

Missed doses often lead to preventable ER visits, hospitalizations, and deteriorating patient outcomes. This can all be avoided with simple caregiver interventions enabled by the Ategenos platform.

“Medication non-adherence is one of healthcare’s most expensive and preventable failures,” said Don DeGolyer, CEO of Ategenos. “This patent cements our leadership in building the first intelligent infrastructure to detect and prevent medication non-adherence in real-time, at scale.”

Ategenos’s mission is to support the health, independence, and daily stability of patients managing chronic conditions. By helping prevent missed doses before they lead to complications, Ategenos’s platform also brings peace of mind to caregivers and offers a scalable solution to reduce the broader economic impact of medication non-adherence.

This IP expands Ategenos’s defensible position as payers, providers, and life sciences leaders seek scalable platforms that generate both better outcomes, lower costs, and real-world data at scale.

Additional IP filings are pending across the U.S., EU, and APAC.

About Ategenos
Ategenos is a Massachusetts-based PharmaTech company improving quality of life for patients and their families with its SmartPatch platform—an advanced transdermal system that combines sustained drug delivery with real-time monitoring and caregiver interventions. The technology reduces health risks, hospitalizations, and the $1T+ global costs caused by missed doses of critical medications. Ategenos’s founding team combines global pharma leadership, MIT-driven innovation, and a proven history of building and scaling healthcare platforms from concept to commercialization.

For Media Inquiries: media@ategenosrx.com
For Strategic Partnerships: partners@ategenosrx.com
For Investment Opportunities: invest@ategenosrx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ategenos-secures-foundational-us-patent-for-first-smartpatch-platform-targeting-1t-medication-non-adherence-crisis-302522415.html

SOURCE Ategenos Pharmaceuticals Inc.